JP2019517505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517505A5 JP2019517505A5 JP2018563009A JP2018563009A JP2019517505A5 JP 2019517505 A5 JP2019517505 A5 JP 2019517505A5 JP 2018563009 A JP2018563009 A JP 2018563009A JP 2018563009 A JP2018563009 A JP 2018563009A JP 2019517505 A5 JP2019517505 A5 JP 2019517505A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- administered
- months
- dose
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130733A JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2023176091A JP2024020202A (ja) | 2016-06-02 | 2023-10-11 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344866P | 2016-06-02 | 2016-06-02 | |
| US62/344,866 | 2016-06-02 | ||
| US201662382839P | 2016-09-02 | 2016-09-02 | |
| US62/382,839 | 2016-09-02 | ||
| PCT/US2017/035521 WO2017210473A1 (en) | 2016-06-02 | 2017-06-01 | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130733A Division JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517505A JP2019517505A (ja) | 2019-06-24 |
| JP2019517505A5 true JP2019517505A5 (https=) | 2020-07-16 |
| JP7641704B2 JP7641704B2 (ja) | 2025-03-07 |
Family
ID=59067913
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563009A Active JP7641704B2 (ja) | 2016-06-02 | 2017-06-01 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2022130733A Pending JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2023176091A Pending JP2024020202A (ja) | 2016-06-02 | 2023-10-11 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130733A Pending JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2023176091A Pending JP2024020202A (ja) | 2016-06-02 | 2023-10-11 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11299543B2 (https=) |
| EP (2) | EP4248989A3 (https=) |
| JP (3) | JP7641704B2 (https=) |
| KR (3) | KR102710067B1 (https=) |
| CN (1) | CN109476752A (https=) |
| AU (2) | AU2017274444B2 (https=) |
| BR (1) | BR112018074619A2 (https=) |
| CA (1) | CA3026246A1 (https=) |
| DK (1) | DK3464368T3 (https=) |
| ES (1) | ES2951650T3 (https=) |
| FI (1) | FI3464368T3 (https=) |
| HU (1) | HUE063911T2 (https=) |
| IL (1) | IL263165A (https=) |
| MX (2) | MX390955B (https=) |
| NZ (1) | NZ748650A (https=) |
| PL (1) | PL3464368T3 (https=) |
| PT (1) | PT3464368T (https=) |
| SG (2) | SG10202101062YA (https=) |
| SI (1) | SI3464368T1 (https=) |
| WO (1) | WO2017210473A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| SG10202101062YA (en) | 2016-06-02 | 2021-03-30 | Bristol Myers Squibb Co | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment |
| CA3077729A1 (en) * | 2017-10-13 | 2019-04-18 | Seattle Genetics, Inc. | Modulating the immune response using antibody-drug conjugates |
| CA3084370A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
| TW202506732A (zh) * | 2018-05-07 | 2025-02-16 | 丹麥商珍美寶股份有限公司 | 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法 |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| EP3902838A4 (en) | 2018-12-26 | 2022-12-21 | Nanjing Legend Biotech Co., Ltd. | Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
| AU2020351751A1 (en) | 2019-09-25 | 2022-04-21 | Seagen Inc. | Combination anti-CD30 ADC, anti-PD-1 and chemotherapeutic for treatment of hematopoietic cancers |
| KR20220114002A (ko) | 2019-12-09 | 2022-08-17 | 씨젠 인크. | Liv1-adc 및 pd-1 길항제를 사용하는 병용 요법 |
| CN111407894B (zh) * | 2020-02-21 | 2022-04-29 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种治疗复发/难治t细胞淋巴瘤的新型联合靶向药物 |
| CA3183602A1 (en) * | 2020-05-13 | 2021-11-18 | Seagen Inc. | Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates |
| JP7652918B2 (ja) | 2021-03-01 | 2025-03-27 | ナントバイオ，インコーポレイテッド | 抗ｃｄ３０モノクローナル抗体及びキメラ抗原受容体 |
| CN118987233A (zh) * | 2024-08-08 | 2024-11-22 | 武汉科技大学 | 治疗经典型霍奇金淋巴瘤的药物组合物及其用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| CN101490085A (zh) * | 2006-06-12 | 2009-07-22 | 特鲁比昂药品公司 | 具有效应功能的单链多价结合蛋白 |
| CL2007003622A1 (es) * | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| JP2016513098A (ja) * | 2013-02-07 | 2016-05-12 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の２−ピロリノドキソルビシン（ｐ２ｐｄｏｘ） |
| ES2878749T3 (es) * | 2013-02-20 | 2021-11-19 | Innate Pharma | Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| WO2015069703A1 (en) * | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| EP3079699A4 (en) * | 2013-12-11 | 2017-07-19 | Glaxosmithkline LLC | Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| SG10202101062YA (en) | 2016-06-02 | 2021-03-30 | Bristol Myers Squibb Co | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment |
| ES2954139T3 (es) | 2016-06-02 | 2023-11-20 | Bristol Myers Squibb Co | Bloqueo de PD-1 con nivolumab en el linfoma de Hodgkin refractario |
-
2017
- 2017-06-01 SG SG10202101062YA patent/SG10202101062YA/en unknown
- 2017-06-01 AU AU2017274444A patent/AU2017274444B2/en active Active
- 2017-06-01 DK DK17730629.7T patent/DK3464368T3/da active
- 2017-06-01 PT PT177306297T patent/PT3464368T/pt unknown
- 2017-06-01 NZ NZ748650A patent/NZ748650A/en unknown
- 2017-06-01 PL PL17730629.7T patent/PL3464368T3/pl unknown
- 2017-06-01 SI SI201731383T patent/SI3464368T1/sl unknown
- 2017-06-01 FI FIEP17730629.7T patent/FI3464368T3/fi active
- 2017-06-01 EP EP23174305.5A patent/EP4248989A3/en not_active Withdrawn
- 2017-06-01 ES ES17730629T patent/ES2951650T3/es active Active
- 2017-06-01 KR KR1020187037834A patent/KR102710067B1/ko active Active
- 2017-06-01 CN CN201780048015.7A patent/CN109476752A/zh active Pending
- 2017-06-01 BR BR112018074619A patent/BR112018074619A2/pt not_active Application Discontinuation
- 2017-06-01 US US16/306,282 patent/US11299543B2/en active Active
- 2017-06-01 SG SG11201810454YA patent/SG11201810454YA/en unknown
- 2017-06-01 MX MX2018014610A patent/MX390955B/es unknown
- 2017-06-01 KR KR1020247031531A patent/KR20240145059A/ko not_active Ceased
- 2017-06-01 EP EP17730629.7A patent/EP3464368B1/en active Active
- 2017-06-01 HU HUE17730629A patent/HUE063911T2/hu unknown
- 2017-06-01 JP JP2018563009A patent/JP7641704B2/ja active Active
- 2017-06-01 WO PCT/US2017/035521 patent/WO2017210473A1/en not_active Ceased
- 2017-06-01 KR KR1020237026623A patent/KR20230119265A/ko not_active Ceased
- 2017-06-01 CA CA3026246A patent/CA3026246A1/en active Pending
-
2018
- 2018-11-21 IL IL263165A patent/IL263165A/en unknown
- 2018-11-27 MX MX2022003571A patent/MX2022003571A/es unknown
-
2022
- 2022-04-07 US US17/715,875 patent/US20220298243A1/en not_active Abandoned
- 2022-08-18 JP JP2022130733A patent/JP2022176973A/ja active Pending
-
2023
- 2023-10-11 JP JP2023176091A patent/JP2024020202A/ja active Pending
-
2024
- 2024-10-30 AU AU2024227762A patent/AU2024227762A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517505A5 (https=) | ||
| JP2019517504A5 (https=) | ||
| JP2019503387A5 (https=) | ||
| JP2019517498A5 (https=) | ||
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| JP2017507155A5 (https=) | ||
| JP2018500332A5 (https=) | ||
| JP2022512781A5 (https=) | ||
| JP2014533279A5 (https=) | ||
| JP2019508433A5 (https=) | ||
| JP2014515036A5 (https=) | ||
| JP2019517512A5 (https=) | ||
| IL313952A (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment | |
| JP2021501776A5 (https=) | ||
| IL312038A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| ES2863369T3 (es) | Terapias inmunoablativas | |
| JP2022511337A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| JP2021523158A5 (https=) | ||
| Cohen | Myeloma: next generation immunotherapy | |
| JP2020510039A5 (https=) | ||
| JP2021518394A5 (https=) | ||
| JP2021523233A5 (https=) | ||
| IL307925A (en) | Combination of an anti-pd-1 antibody and an anti-tissue factor (tf) antibody-drug conjugate for use in the treatment of cancer | |
| JP2014505056A5 (https=) |